Researchers compared the overall survival, cancer-specific survival, and associated costs of trimodal therapy versus radical cystectomy for patients with localized muscle-invasive bladder cancer.
The National Comprehensive Cancer Network released new additions to their guidelines for bladder cancer, including changes to systemic therapy, primary treatments, and adjuvant treatments.
Systemic therapy for bladder cancer is costly and should be weighed against the clinical outcomes likely to be achieved.
A recent study investigated the drug utilization, health care resource utilization, and disease-related costs among patients with metastatic bladder cancer.
Neoadjuvant gemcitabine-based chemotherapy, followed by gemcitabine-based concomitant chemoradiation, may aid in bladder preservation for patients receiving treatment for muscle-invasive bladder cancer in under-resourced countries.
Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research.
Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma is often foregone in community cancer centers and academic centers.
New guidelines have been created involving urology and radiation strategies for the treatment of non-metastatic muscle-invasive bladder cancer.
An anti-PD-1 therapy significantly improves overall survival compared with chemotherapy in previously treated patients with advanced bladder cancer, according to a study presented at the Society for Immunotherapy of Cancer 2016 meeting.